Comparative Pharmacology
Head-to-head clinical analysis: ARISTADA versus LUMATEPERONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARISTADA versus LUMATEPERONE.
ARISTADA vs LUMATEPERONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aripiprazole lauroxil is a prodrug of aripiprazole, a partial agonist at dopamine D2 and serotonin 5-HT1A receptors and an antagonist at 5-HT2A receptors. The mechanism of action in schizophrenia and bipolar I disorder is thought to be mediated through these receptor interactions.
Lumateperone is an atypical antipsychotic with a unique mechanism of action: it acts as a 5-HT2A receptor antagonist, a dopamine D2 receptor antagonist, and a serotonin reuptake inhibitor. It also modulates glutamate via enhanced AMPA and NMDA receptor activity.
Initial dose: 675 mg intramuscularly every 4 weeks for the first 2 doses, then maintenance dose of 882 mg intramuscularly every 4 weeks. Alternatively, 1064 mg intramuscularly every 6 weeks after appropriate initiation.
42 mg orally once daily, taken with food and at least 240 mL of water, with a titration schedule: 42 mg daily for 7 days, then 21 mg twice daily thereafter.
None Documented
None Documented
Terminal elimination half-life of aripiprazole lauroxil (the prodrug in ARISTADA) is approximately 54 days (range 29-74 days) after IM injection, allowing monthly dosing.
Terminal elimination half-life is approximately 13 hours in the plasma, supporting once-daily dosing. Steady state is reached within 5–7 days.
Primarily renally excreted (approximately 60% as metabolites, <1% unchanged). Fecal elimination accounts for about 20%.
Approximately 80% of the dose is excreted in feces (as unchanged drug and metabolites) and about 11% in urine. Less than 1% is excreted as unchanged lumateperone in urine.
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic